Joana Balça-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joana Balça-Silva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Anália Do Carmo
Clinical Pathology Service, Unidade Local de Saúde de Coimbra, Coimbra, Portugal
6 shared publications - Ana Bela Sarmento-Ribeiro
Laboratório de Oncobiologia e Hematologia, Clinica Universitária de Hematologia, FMUC—Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
5 shared publications - Diana Matias
Gulbenkian Institute for Molecular Medicine (GIMM), Edifício Egas Moniz, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
5 shared publications - Maria Celeste Lopes
Faculdade de Farmácia da Universidade de Coimbra, 3000-548 Coimbra, Portugal
5 shared publications - Vivaldo Moura-Neto
Postgraduate Program in Medicine (Anatomical Pathology), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, Brazil
5 shared publications - Henrique Girão
Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2 shared publications
Latest Publications
- 1 October 2019
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 58, 130-141
Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies
- 1 October 2019
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 58, 130-141
Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies
- 1 September 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 370 (1) , 68-77
Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity
- 1 September 2018
- Published by Elsevier in Experimental Cell Research
- Vol. 370 (1) , 68-77
Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity
- Open Access
- 1 August 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (4) , 555-569
The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells
- 1 August 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (4) , 555-569
Open AccessThe Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells
- 1 April 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1850 (4) , 722-732
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines
- 1 April 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1850 (4) , 722-732
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines
- 1 January 2015
- Published by Springer Nature
- p. 87-117
The Role of the Cytoskeleton in Cell Migration, Its Influence on Stem Cells and the Special Role of GFAP in Glial Functions
- 1 January 2015
- Published by Springer Nature
- p. 87-117
The Role of the Cytoskeleton in Cell Migration, Its Influence on Stem Cells and the Special Role of GFAP in Glial Functions
- Open Access
- 1 April 2013
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 14 (4) , 287-294
PKC signaling in glioblastoma
Glioblastoma Multiforme (GBM) is the most aggressive brain tumor characterized by intratumoral heterogeneity at cytopathological, genomic and transcriptional levels. Despite the efforts to develop new therapeutic strategies the median survival of GBM patients is 12−14 months. Results from large-scale gene expression profile studies confirmed that the genetic alterations in GBM affect pathways controlling cell cycle progression, cellular proliferation and survival and invasion ability, which may explain the difficulty to treat GBM patients. One of the signaling pathways that contribute to the aggressive behavior of glioma cells is the protein kinase C (PKC) pathway. PKC is a family of serine/threonine-specific protein kinases organized into three groups according the activating domains. Due to the variability of actions controlled by PKC isoforms, its contribution to the development of GBM is poorly understood. This review intends to highlight the contribution of PKC isoforms to proliferation, survival and invasive ability of glioma cells.
- 1 April 2013
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 14 (4) , 287-294
Open AccessPKC signaling in glioblastoma
Glioblastoma Multiforme (GBM) is the most aggressive brain tumor characterized by intratumoral heterogeneity at cytopathological, genomic and transcriptional levels. Despite the efforts to develop new therapeutic strategies the median survival of GBM patients is 12−14 months. Results from large-scale gene expression profile studies confirmed that the genetic alterations in GBM affect pathways controlling cell cycle progression, cellular proliferation and survival and invasion ability, which may explain the difficulty to treat GBM patients. One of the signaling pathways that contribute to the aggressive behavior of glioma cells is the protein kinase C (PKC) pathway. PKC is a family of serine/threonine-specific protein kinases organized into three groups according the activating domains. Due to the variability of actions controlled by PKC isoforms, its contribution to the development of GBM is poorly understood. This review intends to highlight the contribution of PKC isoforms to proliferation, survival and invasive ability of glioma cells.
- 1 May 2012
- Vol. 32 (5) , 1603-9
Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines.
The miR-34 family, under-expressed in-non small cell lung cancers (NSCLCs), are effectors of p53 activation upon irradiation of cells. We evaluated whether the miR-34b overexpression modulates the NSCLCs response to radiation. NSCLC cell lines A549 with V-KI-RAS2 Kirsten Rat Sarcoma viral oncogene (KRAS) codon 12 mutation and with wild type p53, and H1299, not expressing p53, were irradiated after transfection with pre-miR-34b. Cell survival was assessed by clonogenic survival assays. The apoptosis and the cell cycle were evaluated by flow cytometry. In the A549 cell line, overexpression of miR-34b significantly reduced cell survival at lower than 4 Gy radiation doses. There was a significant reduction in B-cell CLL/lymphoma 2 (BCL2) expression but no significant differences were observed in the apoptotic cell population or the cycle profile. No significant effect was recorded in the H1299 irradiated cells. In the p53 wild type, KRAS mutated NSCLC cells, the overexpression of miR-34b increases radiosensitivity at low doses of radiation.
- 1 May 2012
- Vol. 32 (5) , 1603-9
Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines.
The miR-34 family, under-expressed in-non small cell lung cancers (NSCLCs), are effectors of p53 activation upon irradiation of cells. We evaluated whether the miR-34b overexpression modulates the NSCLCs response to radiation. NSCLC cell lines A549 with V-KI-RAS2 Kirsten Rat Sarcoma viral oncogene (KRAS) codon 12 mutation and with wild type p53, and H1299, not expressing p53, were irradiated after transfection with pre-miR-34b. Cell survival was assessed by clonogenic survival assays. The apoptosis and the cell cycle were evaluated by flow cytometry. In the A549 cell line, overexpression of miR-34b significantly reduced cell survival at lower than 4 Gy radiation doses. There was a significant reduction in B-cell CLL/lymphoma 2 (BCL2) expression but no significant differences were observed in the apoptotic cell population or the cycle profile. No significant effect was recorded in the H1299 irradiated cells. In the p53 wild type, KRAS mutated NSCLC cells, the overexpression of miR-34b increases radiosensitivity at low doses of radiation.